Equities research analysts at Leerink Swann started coverage on shares of AC Immune (NASDAQ:ACIU) in a report released on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $18.00 price target on the stock. Leerink Swann’s price target would indicate a potential upside of 101.57% from the company’s previous close.

A number of other research firms have also recently commented on ACIU. BidaskClub cut AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. Zacks Investment Research raised AC Immune from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Monday, August 6th. ValuEngine cut AC Immune from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Finally, HC Wainwright set a $18.00 price target on AC Immune and gave the stock a “buy” rating in a report on Thursday, August 9th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. AC Immune presently has an average rating of “Hold” and an average price target of $15.00.

AC Immune stock opened at $8.93 on Monday. The company has a quick ratio of 9.65, a current ratio of 9.65 and a debt-to-equity ratio of 0.01. AC Immune has a 52 week low of $7.16 and a 52 week high of $17.40. The firm has a market cap of $574.98 million, a PE ratio of -30.27 and a beta of 1.09.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in shares of AC Immune by 131.6% during the 3rd quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock valued at $418,000 after purchasing an additional 29,720 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of AC Immune during the 3rd quarter valued at about $2,279,000. JPMorgan Chase & Co. bought a new stake in shares of AC Immune during the 3rd quarter valued at about $142,000. GSA Capital Partners LLP bought a new stake in shares of AC Immune during the 3rd quarter valued at about $110,000. Finally, Compagnie Lombard Odier SCmA boosted its position in shares of AC Immune by 858.3% during the 3rd quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock valued at $268,000 after purchasing an additional 30,039 shares in the last quarter. Hedge funds and other institutional investors own 16.83% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: Compound Interest and Why It Matters When Investing

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.